专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023008988A1 МУЛЬТИСУБЪЕДИНИЧНАЯ ВАКЦИНА ПРОТИВ SARS-COV-2 审中-公开
公开(公告)号：WO2023008988A1
公开(公告)日：2023-02-02
申请号：PCT/KZ2022/000010
申请日：2022-07-29
申请人： АВТОНОМНАЯ ОРГАНИЗАЦИЯ ОБРАЗОВАНИЯ "НАЗАРБАЕВ УНИВЕРСИТЕТ"
发明人： САЙЕД, Али , САЙЕД, Хани Абиди
IPC分类号： A61K47/42 , A61K38/17 , C07K14/165 , C07K14/08 , C12N5/0781 , C12N5/0783 , A61P31/14
摘要： Заявлена вакцина, которая сочетает эволюционно сохраненные В- и Т- клеточные эпитопы коронавирусов человека, включая SARS-CoV-2, для обеспечения как гуморального, так и клеточного иммунитета. Высокая степень сходства последовательностей между SARS-CoV-2 и другими коронавирусами человека (HCoV) открывает возможность для разработки вакцин, которые обеспечат защиту от SARS-CoV-2 и его текущих и будущих новых вариантов, с перекрестной защитой от других HCoV. Проведенный биоинформационный анализ, идентифицирующий эпитопы Т- клеток и В-клеток, происходящие из последовательностей спайков, мембран, нуклеокапсидов и оболочек белков, показал, что они эволюционно консервативны среди семи основных HCOV. Эволюционное сохранение этих эпитопов указывает на то, что они могут играть решающую роль в приспособленности вируса и, следовательно, вряд ли мутируют во время репликации вируса, что делает такие эпитопы привлекательными кандидатами для вакцины. Наша разработанная вакцинная конструкция включает 12 Т-клеточных и шесть В-клеточных эпитопов, которые сохраняются среди HCOV.

2. 发明申请

WO2023283641A1 MODIFIED EASTERN EQUINE ENCEPHALITIS VIRUSES, SELF-REPLICATING RNA CONSTRUCTS, AND USES THEREOF 审中-公开
公开(公告)号：WO2023283641A1
公开(公告)日：2023-01-12
申请号：PCT/US2022/073563
申请日：2022-07-08
申请人： REPLICATE BIOSCIENCE, INC.
发明人： WANG, Nathaniel Stephen , MIYAKE-STONER, Shigeki Joseph , ALIAHMAD, Parinaz
IPC分类号： C12N15/86 , C07K14/005 , C12N7/00 , C12N15/90 , C07K14/08
摘要： The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons (e.g., self-replicating RNAs), pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.

3. 发明申请

WO2022232612A1 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE 审中-公开
公开(公告)号：WO2022232612A1
公开(公告)日：2022-11-03
申请号：PCT/US2022/027082
申请日：2022-04-29
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： HO, Mitchell , KWONG, Peter D. , DUAN, Zhijian , SUN, Yaping , CHEUNG, Sao-Fong , GORMAN, Jason J.
IPC分类号： A61K39/12 , A61P31/12 , C07K14/08 , A61K39/00
摘要： Single-domain monoclonal antibodies that specifically bind Lassa virus glycoprotein (GPC) are described. The single-domain antibodies ("nanobodies") were isolated from camel (VHH) and shark variable new antigen (VNAR) phage display libraries panned against a stabilized form of the GPC trimer. The GPC-specific nanobodies, and conjugates thereof, can be used for the diagnosis and treatment of a Lassa virus infection.

4. 发明申请

WO2022087031A1 COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES 审中-公开
公开(公告)号：WO2022087031A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/055699
申请日：2021-10-19
申请人： DUKE UNIVERSITY , KORBER, Bette, T. , WAGH, Kshitij, G.
发明人： SAUNDERS, Kevin, O. , HAYNES, Barton, F.
IPC分类号： C07K14/005 , C07K14/155 , A61K39/12 , C07K14/08
摘要： The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.

5. 发明申请

WO2022086854A1 METHODS OF USING PASSIVE IMMUNITY TO DECREASE TRANSMISSION OF INFECTIOUS DISEASES 审中-公开
公开(公告)号：WO2022086854A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/055415
申请日：2021-10-18
申请人： CAMAS INCORPORATED
发明人： MITTENESS, Bradley M. , SIMPLOT, Scott , HAWKINS, Michelle L. , ROBLEY, Brian , LARSON, Philip , HULL, Jason
IPC分类号： A61P11/00 , A61P31/14 , A61P31/16 , C07K14/08 , C07K14/165 , C07K14/175 , C07K14/18 , C07K16/02 , C07K16/10 , C07K16/12 , C12N15/40 , C12N15/44 , C12N15/50 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/215
摘要： Egg laying birds on egg farms are inoculated with one or more disease antigens from microbial organisms causing infectious diseases. Egg material from the eggs contain one or more avian antibodies against the microbial organisms and these avian antibodies can specifically bind and/or neutralize the microbial organisms upon consumption by individuals in a population. Egg products comprising the one or more avian antibodies are provided to individuals in the population to increase the prevalence of avian antibodies against the microbial organism in the population. The egg products are provided in a variety of formulations for protecting individuals against the disease and/or for reducing the susceptibility for acquiring the disease. Egg products effective against infections of SARS-CoV-2 in individuals and for reducing the incidence of Covid-19 are provided. Methods are provided to decrease the infection rates of infectious diseases in a population of individuals.

6. 发明申请

WO2021207411A1 TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION 审中-公开
公开(公告)号：WO2021207411A1
公开(公告)日：2021-10-14
申请号：PCT/US2021/026257
申请日：2021-04-07
申请人： CHRYSALIS BIOTHERAPEUTICS , CARNEY, Darrell , SOWER, Laurie, E.
发明人： CARNEY, Darrell , SOWER, Laurie, E.
IPC分类号： C07K14/005 , C07K14/165 , C07K14/08
摘要： Certain embodiments are directed to using TP508 as a drug that can restore prevent alveolar damage, reducing pulmonary edema and prevent respiratory failure and mortality-associated progression of COVID-19.

7. 发明申请

WO2020035497A1 STABILIZED FILOVIRUS GLYCOPROTEIN TRIMERS 审中-公开
公开(公告)号：WO2020035497A1
公开(公告)日：2020-02-20
申请号：PCT/EP2019/071732
申请日：2019-08-13
申请人： JANSSEN VACCINES & PREVENTION B.V.
发明人： LANGEDIJK, Johannes, Petrus, Maria , RUTTEN, Lucy , BLOKLAND, Sven
IPC分类号： A61K39/12 , C07K14/08
摘要： Filovirus glycoprotein mutations that stabilize the trimeric form of the glycoprotein are provided. The Filovirus glycoproteins have certain amino acid substitutions at specified positions in the glycoprotein sequence. The Filovirus glycoproteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to a Filovirus glycoprotein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the Filovirus glycoproteins, as well as compositions containing the Filovirus glycoproteins, nucleic acid, and vectors.

8. 发明申请

WO2019104439A1 MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS COMPRISING MODIFIED NOROVIRUS VP1 PROTEINS 审中-公开
公开(公告)号：WO2019104439A1
公开(公告)日：2019-06-06
申请号：PCT/CA2018/051530
申请日：2018-11-30
申请人： MEDICAGO INC.
发明人： LAVOIE, Pierre-Olivier , D'AOUST, Marc-Andre
IPC分类号： C12N15/40 , A01H5/00 , A61K39/12 , A61P31/14 , A61P37/04 , C07K14/08 , C07K16/10 , C12N15/82 , C12N5/10 , C12N7/01 , C12P21/02
摘要： Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.

9. 发明申请

WO2018231974A1 COMPOSITION AND ADMINISTRATION OF CHIMERIC GLYCOPROTEIN LYSSAVIRUS VACCINES FOR COVERAGE AGAINST RABIES 审中-公开
公开(公告)号：WO2018231974A1
公开(公告)日：2018-12-20
申请号：PCT/US2018/037322
申请日：2018-06-13
申请人： THOMAS JEFFERSON UNIVERSITY , ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
发明人： SCHNELL, Matthias , FISHER, Christine Rettew , WIRBLICH, Christoph , TAN, Gene
IPC分类号： A61K39/12 , A61K39/205 , C07K14/005 , C07K14/08 , C07K14/145 , C12N15/09 , C12N15/86
CPC分类号： A61K39/12 , A61P31/14 , C07K14/005 , C07K2319/40 , C12N15/09 , C12N2760/20022 , C12N2760/20034 , C12N2760/20122 , C12N2760/20134
摘要： The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain.; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.

10. 发明申请

WO2018111735A1 A CELL-BASED REPORTER ASSAY FOR LIVE VIRUS VACCINES 审中-公开
公开(公告)号：WO2018111735A1
公开(公告)日：2018-06-21
申请号：PCT/US2017/065501
申请日：2017-12-11
申请人： MERCK SHARP & DOHME CORP. , MEYER, Brian, K. , BHAMBHANI, Akhilesh , BLUE, Jeffrey, T.
发明人： MEYER, Brian, K. , BHAMBHANI, Akhilesh , BLUE, Jeffrey, T.
IPC分类号： A61K35/76 , A61K39/12 , C07K14/08 , C12N7/01 , C12N15/33 , C12Q1/66 , C12Q1/70
CPC分类号： C12Q1/04 , C12Q1/66
摘要： The present invention relates to a cell-based reporter assay for determining viral potency comprising A) transfecting cells maintained in media with a promoter-reporter construct and generating reporter enzyme within the cells; B) infecting cells with a live virus or live virus vaccine wherein reporter enzyme is released into media; and C) measuring reporter enzyme intensity in media.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式